Abstracts tagged "interstitial lung disease"

Abstract Number: 1158 • ACR Convergence 2020
Clinical Features and Outcomes in STING-Associated Vasculopathy with Onset in Infancy (SAVI)
Sofia Torreggiani¹, Sara Alehashemi², Jacob Mitchell¹, Gema Souto Adeva¹, Bin Lin¹, Jenna Wade¹, Gina Montealegre Sanchez³, Abdulrahman Alrasheed⁴, Sibel Balci⁵, Roberta Berard⁶, Borzutzky Arturo⁷, Jürgen Brunner⁸, Bjoern Buehring⁹, Al Adba Buthaina¹⁰, Caterina Cancrini¹¹, John Carter¹², Mireia Corbeto Lopez¹³, Fabrizio De Benedetti¹⁴, Huy Do¹⁵, Gregor Dueckers¹⁶, Les Folio¹⁵, Antonella Insalaco¹⁷, Rabia Miray Kisla Ekinci⁵, Michael Miller¹⁸, Marco Montes Cano¹⁹, Marie-Paule Morin²⁰, Seza Ozen²¹, Lucia Pacillo¹¹, Suzanne Ramsey²², Adam Reinhardt²³, Dax Rumsey²⁴, Laisa Santiago²⁵, Grant Schulert²⁶, Benjamin Wright²⁷, Adriana de Jesus²⁸ and Raphaela Goldbach-Mansky²⁹, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ³NIAID/NIH, Rockville, MD, ⁴King Abdullah Specialized Children Hospital, Riyadh, Riyadh, Saudi Arabia, ⁵Department of Pediatric Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey, ⁶London Health Sciences Centre, London, ON, Canada, ⁷Pontificia Universidad Católica de Chile, Santiago, Chile, ⁸Tirol Kliniken, Innsbruck, Innsbruck, Austria, ⁹Rheumazentrum Ruhrgebiet, Ruhr-University-Bochum, Herne, Germany, ¹⁰Sidra Medicine, Doha, Doha, Qatar, ¹¹Unit of Immune and Infectious Diseases, Scientific Institute for Research and Healthcare (IRCCS) Childrens’ Hospital Bambino Gesù, University Department of Pediatrics (DPUO); Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy, ¹²University of South Florida, Tampa, FL, ¹³Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, ¹⁴Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ¹⁵Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, ¹⁶Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Germany, Krefeld, Germany, ¹⁷Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ¹⁸Feinberg School of Medicine, Northwestern University Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ¹⁹Hospital Universitario Virgen del Rocío, Sevilla, Sevilla, Spain, ²⁰Université de Montréal, CHU Sainte-Justine, Montréal, Canada, ²¹Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, ²²IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ²³Boys Town National Research Hospital, Omaha, Omaha, NE, ²⁴Alberta Health Services – Edmonton Zone (Stollery Children’s Hospital), University of Alberta, Edmonton, AB, Canada, ²⁵Johns Hopkins All Children's Hospital, St. Petersburg, FL, ²⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²⁷Mayo Clinic, Phoenix, AZ, ²⁸Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ²⁹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: STING-Associated Vasculopathy with Onset in Infancy (SAVI) is an autoinflammatory interferonopathy caused by gain-of-function mutations in STING1, characterized by peripheral vasculopathy and interstitial lung…
Abstract Number: 1606 • ACR Convergence 2020
Mortality with Idiopathic Inflammatory Myositis in an Academic Hospital Setting: A Five-year Retrospective Study
Jaspreet Kaler¹, Zareen Vaghaiwalla², Gurjit Kaeley³ and Myint Thway⁴, ¹University of Florida - Jacksonville, Jacksonville, FL, ²University of Florida Jacksonville, Jacksonville, FL, ³University of Florida College of Medicine - Jacksonville, Jacksonville, FL, ⁴University of Florida- Jacksonville, ponte vedra, FL
Background/Purpose: Idiopathic inflammatory myositis is a diverse group of muscle diseases characterized by muscle inflammation and dysfunction. Approximately 3-7/100,000 cases are diagnosed per year in…
Abstract Number: 0233 • ACR Convergence 2020
Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients
C. Fernandez-Diaz¹, Santos Castañeda², Rafael Melero³, Francisco Miguel Ortiz Sanjuan⁴, Antonio Juan-Mas⁵, Carmen Carrasco Cubero⁶, Raquel Almodovar⁷, Sebastian Rodriguez-Garcia⁸, C. Aguilera-Cros⁹, Ignacio Villa¹⁰, S. Ordoñez¹¹, Enrique Raya¹², C. Ojeda¹³, Manuel Jose Moreno-Ramos¹⁴, Gema Bonilla¹⁵, Susana Romero-Yuste¹⁶, Ana Ruibal-Escribano¹⁷, Jose Luis Andreu Sanchez¹⁸, R. Exposito¹⁹, Javier Loricera²⁰, Natalia Mena-Vazquez²¹, Ana Urriticoechea²², C. Peralta²³, Luis Arboleya²⁴, Francisco Javier Narváez²⁵, O. Maiz²⁶, Julia Fernandez Melon²⁷, P Vela²⁸, Ivan Castellvi²⁹, I. Cabezas³⁰, Alejandra Lopez Robles³¹, Patricia Carreira Delgado³², Juan M. Blanco-Madrigal³³, N. Del-val-del-amo³⁴, E Salgado³⁵, B. Garcia-magallon³⁶, Cristina Hidalgo Calleja³⁷, Mireia Corbeto Lopez³⁸, A. Perez³⁹, S. Castro⁴⁰, Juan Ramón De dios⁴¹, Andrea García Valle⁴², R Lopez⁴³, Angel García Aparicio⁴⁴, EC Cervantes⁴⁵, C Gonzalez⁴⁶, N Alvarez-Rivas⁴⁷, L. Perez⁴⁸, Miguel Ángel González-Gay⁴⁹ and Ricardo Blanco⁵⁰, ¹H. Marqués de Valdecilla, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³CHU. VIgo, Vigo, Spain, ⁴Rheumatology Department, HUP La Fe, Valencia, Spain, ⁵Son Llàzer University Hospital, Mallorca, Spain, ⁶H. Mérida, Mérida, Spain, ⁷Fundación Alcorcón University Hospital, Madrid, ⁸La Princesa University Hospital, Madrid, Spain, ⁹H.Virgen del Rocio, Sevilla, Spain, ¹⁰H. Torrelavega, Santander, Spain, ¹¹H. Arnau Vilanova, LLeida, Spain, ¹²San Cecilio Clinic Universitary Hospital, Granada, Spain, ¹³H. Virgen de la Macarena, Sevilla, Spain, ¹⁴Arrixaca University Hospital, Murcia, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶H Pontevedra, Coruna, Spain, ¹⁷Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹⁹H. Laredo, Laredo, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Hospital Regional Universitario de Málaga, Málaga, Spain, ²²Can Misses, Ibiza, Spain, ²³H. Clinico Zaragoza, Zaragoza, Spain, ²⁴H. Oviedo, Oviedo, Spain, ²⁵Hospital Bellvitge, BARCELONA, Spain, ²⁶H. Donosti, Donosti, Spain, ²⁷H. Son Espases, Mallorca, Spain, ²⁸H Alicante, Alicante, Spain, ²⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³⁰H. Río Ortega, Valladolid, Spain, ³¹H. León, León, ³²H. 12 de octubre, Madrid, Spain, ³³Basurto University Hospital, Bilbao, Spain, ³⁴Complejo Hospitalario de Navarra, Pamplona, Spain, ³⁵CHU Ourense, Ourense, Spain, ³⁶H. Huesca, Zaragoza, Spain, ³⁷Hospital Universitario Salamanca, Salamanca, Spain, ³⁸Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, ³⁹H. Puerta del Mar, Cadiz, Spain, ⁴⁰H. Joan XXIII, Tarragona, Spain, ⁴¹H. Alava, Alava, Spain, ⁴²H. Palencia, Palencia, Spain, ⁴³H. Negrin, Las Palmas, Spain, ⁴⁴H. Mostoles, Madrid, Spain, ⁴⁵H. Santiago de compostela, Santiago, Spain, ⁴⁶H. Valladolid, Valladolid, Spain, ⁴⁷H. S Agustin, Aviles, Spain, ⁴⁸Hospital Universitario Virgen de las Nieves, Granada, Spain, ⁴⁹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: To assess the efficacy of abatacept (ABA) in Rheumatoid Arthritis (RA) patients with Interstitial Lung Disease (ILD) (RA-ILD).Methods: Observational multicenter study of RA-ILD patients…
Abstract Number: 1048 • ACR Convergence 2020
Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib
Eric Matteson¹, Oliver Distler², Jörg HW Distler³, Masataka Kuwana⁴, Janet Pope⁵, James Seibold⁶, Alexandra James⁷, Rozsa Schlenker-Herceg⁸, Klaus Rohr⁷ and Kevin Flaherty⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ³University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, SC, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁹Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: In the randomized placebo-controlled INBUILD trial in patients with chronic fibrosing ILDs with a progressive phenotype, nintedanib reduced the rate of decline in forced…
Abstract Number: 1171 • ACR Convergence 2020
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests. Results from the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Bernd Hinrichs², Kathryn Torok³, Maria Jose Santos⁴, Ozgur Kasapcopur⁵, Amra Adrovic⁶, Valda Stanevicha⁷, Flavio Sztajnbok⁸, Maria Teresa Terreri⁹, Ana Paula Sakamoto¹⁰, Ekaterina Alexeeva¹¹, Jordi Anton¹², Maria Katsicas¹³, Vanessa Smith¹⁴, Tadej Avcin¹⁵, Edoardo Marrani¹⁶, Mikhail Kostik¹⁷, Thomas Lehman¹⁸, Walter Alberto Sifuentes-Giraldo¹⁹, Simone Appenzeller²⁰, Mahesh Janarthanan²¹, Monika Moll²², Dana Nemcova²³, Dieneke Schonenberg-Meinema²⁴, Cristina Battagliotti²⁵, Lillemor Berntson²⁶, Blanca Bica²⁷, Jürgen Brunner²⁸, Patricia Costa Reis²⁹, Despina Eleftheriou³⁰, Liora Harel³¹, Gerd Horneff³², Tilmann Kallinich³³, Dragana Lazarevic³⁴, Kirsten Minden³⁵, Susan Nielsen³⁶, Farzana Nuruzzaman³⁷, Anjali Patwardhan³⁸, Yosef Uziel³⁹ and Nicola Helmus⁴⁰, ¹Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ²Kinderklinik Heidberg Pulmologie, Hamburg, Germany, ³University of Pittsburgh, Pittsburgh, PA, ⁴Hospital Garcia de Orta, Almada, Portugal, ⁵PRINTO, Istituto Giannina Gaslini, Genova, Italy, ⁶Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, ⁷Riga Stradins University, Riga, Latvia, ⁸Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Federal University of São Paulo, São Paulo, Brazil, ¹⁰UNIFESP, Sao Paulo, Brazil, ¹¹Scientific Center of Children’s Health of RAMS, Moscow, Russia, ¹²Sant Joan de Déu Hospital, Madrid, Spain, ¹³Hospital de Pediatria, Buenos Aires, Argentina, ¹⁴Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, ¹⁵Ljubljana University Medical Centre, Ljubljana, Slovenia, ¹⁶University of Florence, Firenze, Italy, ¹⁷Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁸Hospital for Special Surgery, New York, ¹⁹Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁰Unicamp, Campinas, Brazil, ²¹Sri Ramachandra University, Chennai, India, ²²University of Tübingen, Tübingen, Germany, ²³General University Hospital, Prague, Czech Republic, ²⁴Amsterdam UMC, Amsterdam, Netherlands, ²⁵Children's Hospital Dr. Orlando Alassia, Santa Fee, Argentina, ²⁶Uppsala University Hospital, Uppsala, Sweden, ²⁷Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), Rio de Janeiro, Brazil, ²⁸Tirol Kliniken, Innsbruck, Innsbruck, Austria, ²⁹Hospital de Santa Maria, Lisbon, Portugal, ³⁰Great Ormond Street Hospital, London, United Kingdom, ³¹Clalit Health Services, Nettnja, Israel, ³²Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ³³Charite, Berlin, Germany, ³⁴KC Niš, Nis, Serbia, ³⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ³⁶Rigshospitalet, Copenhagen, Denmark, ³⁷Stony Brook Children's Hospital, Stony Brook, NY, ³⁸University of Missouri, Columbia, ³⁹Meir Medical Center, Kfar Saba, Israel, ⁴⁰Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) has a prevalence in around 3 in a million children. Pulmonary involvement occurs in approximately 40 % in the international…
Abstract Number: 1695 • ACR Convergence 2020
Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung
David Moreno McNeill¹, Miriah Gillispie-Taylor², Kevin Baszis³, Edouard Sayad¹, Manuel Silva Carmona¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, ³Washington Univ School of Medicine, St Louis, MO
Background/Purpose: A subset of juvenile dermatomyositis (JDM), clinically amyopathic dermatomyositis (CADM), is uncommon and mainly described in adults. CADM is classically characterized by skin ulcerations,…
Abstract Number: 0279 • ACR Convergence 2020
Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus
Naci Senkal¹, Esen Kiyan², Elif Kocasoy-Orhan³, Ali Demir⁴, Mehmet Aydogan⁵, Yasemin Yalcinkaya⁶, Ahmet Gul⁶, Murat Inanc⁷, Mahdume Lale Öcal⁶ and Bahar Artım-Esen⁶, ¹Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ²Department of Chest Disease, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ³Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁴Fulya Radiologic Imaging Center, İstanbul, Turkey, ⁵Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁶Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁷Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: The prevalence of SLE pulmonary involvement varies depending on several factors, including diagnostic methods. In this study, we sought to determine the frequency of…
Abstract Number: 1049 • ACR Convergence 2020
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
Paul Dellaripa¹, Martin Aringer², Anna Maria Hoffmann-Vold³, Clive Kelly⁴, Shikha Mittoo⁵, Alexandra James⁶, Klaus Rohr⁶, Susanne Stowasser⁶ and Yoshikazu Inoue⁷, ¹Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle upon Tyne, United Kingdom, ⁵University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁷Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan, Sakai City, Osaka, Japan
Background/Purpose: In the INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in patients with…
Abstract Number: 1194 • ACR Convergence 2020
MUC5B Promoter Variant rs35705950 and Risk Stratification for Rheumatoid Arthritis – Interstitial Lung Disease
Pierre-Antoine Juge¹, Fabienne Louis-Sidney², Benjamin Granger³, Joanna Kedra⁴, Marie-Pierre Debray⁵, Esther Ebstein¹, Raphaël Borie⁶, Arnaud Constantin⁷, Bernard Combe⁸, Rene-Marc Flipo⁹, Xavier Mariette¹⁰, Olivier Vittecoq¹¹, Alain Saraux¹², Guillermo Carvajal Alegria¹³, Jean Sibilia¹⁴, Francis Berenbaum¹⁵, Caroline Kannengiesser¹⁶, Bruno Crestani⁶, Catherine Boileau¹⁶, Bruno Fautrel¹⁷ and Philippe Dieude¹⁸, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²Service de Rhumatologie, CHU de Fort de France, Martinique, France, Fort de France, France, ³Département de Biostatistiques, Santé Publique et Information Médicale, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Paris, France, ⁴Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ⁵Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁶Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁷Hospital Pierre Paul Riquet, Toulouse, France, ⁸University of Montpellier, Montpellier, France, ⁹Lille University Hospital, Lille, France, ¹⁰Paris-Sud University, Rueil-Malmaison, France, ¹¹University Hospital of Rouen, Rouen, France, ¹²Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ¹³CHU de Brest, Service de Rhumatologie, Brest, France, ¹⁴CHU Strasbourg, Service de Rhumatologie, Strasbourg, France, ¹⁵AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ¹⁶Université de Paris, Hôpital Bichat, Service de Génétique, AP-HP, Paris, Paris, France, ¹⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹⁸Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) detected in 20 to 60% of patients with RA on high-resolution computed-tomography…
Abstract Number: 2034 • ACR Convergence 2020
Resolving Phenotypic and Prognostic Differences in Interstitial Lung Disease Related to Systemic Sclerosis by Computed Tomography-based Radiomics
Janine Schniering¹, Malgorzata Maciukiewicz¹, Hubert Gabrys², Matthias Brunner¹, Christian Blütghen³, Chantal Meier¹, Sophie Braga-Lagache⁴, Anne-Christine Ulgry⁴, Manfred Heller⁴, Oliver Distler¹, Matthias Guckenberger², Havard Fretheim⁵, Anna-Maria Hoffmann-Vold⁵, Christos Nakas⁶, Thomas Frauenfelder³, Stephanie Tanadini-Lang² and Britta Maurer⁷, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ²Department of Radiation Oncology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ³Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ⁴Proteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, Switzerland, Bern, Switzerland, ⁵Department of Rheumatology, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Norway, Oslo, Norway, ⁶Laboratory of Biometry, University of Thessaly, Volos, Greece, Volos, Greece, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich
Background/Purpose: Radiomics describes the in-depth analysis of tissue phenotypes by computational retrieval of high-dimensional quantitative imaging features including tissue intensity, texture, and wavelet characteristics. Here,…
Abstract Number: 0383 • ACR Convergence 2020
Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials
Elizabeth Volkmann¹, Ning Li², Michael Roth², Carol Feghali-Bostwick³, Richard Silver⁴, DeAnna Baker Frost⁵, Shervin Assassi⁶, Grace Kim², Jonathan Goldin² and Donald Tashkin², ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles, ³The Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, ⁵The Medical University of South Carolina, Charleston, ⁶University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Although systemic sclerosis (SSc) disproportionately affects females compared with males [1], observational studies have demonstrated higher mortality rates in males with SSc [2]. This…
Abstract Number: 1050 • ACR Convergence 2020
Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center
Belén Atienza-Mateo¹, Sara Remuzgo-Martínez², Diana Prieto-Peña¹, Víctor Manuel Mora Cuesta³, David Iturbe-Fernández³, Sonia Fernández Rozas¹, Alfonso Corrales¹, José Manuel Cifrián² and Miguel Ángel González-Gay⁴, ¹Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, ³Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: The presence of interstitial lung disease (ILD) in patients with autoimmune diseases (AD)s influences significantly on their morbidity and mortality [1]. Different treatment strategies…
Abstract Number: 1195 • ACR Convergence 2020
MUC5B rs35705950 and Rheumatoid Arthritis Associated Interstitial Lung Disease Progression
Pierre-Antoine Juge¹, Joshua Solomon², Romain Garofoli³, Joyce S. Lee⁴, Fabienne Louis-Sidney⁵, Esther Ebstein¹, Jorge Rojas-Serrano⁶, Montserrat I. Gonzalez-Perez⁶, Mayra Mejia⁶, Ivette Buendia-Roldan⁶, Ramces Falfan-Valencia⁷, Enrique Ambrocio-Ortiz⁷, Effrosyni Manali⁸, Spyros A. Papiris⁸, Theofanis Karageorgas⁹, Dimitrios Boumpas⁹, Katarina Antoniou¹⁰, Coline H.M. van Moorsel¹¹, Joanne van Der Vis¹¹, Yaël A. de Man¹¹, Jan C. Grutters¹¹, Caroline Kannengiesser¹², Raphaël Borie¹³, Lidwine Wemeau-Stervinou¹⁴, Rene-Marc Flipo¹⁵, Hilario Nunes¹⁶, Yurdagul Uzunhan¹⁷, Dominique Valeyre¹⁸, Nathalie Saidenberg Kermanac'h¹⁹, Marie-Christophe Boissier²⁰, Christophe Richez²¹, Thierry Schaeverbeke²², Tracy J. Doyle²³, Paul Wolters²⁴, Marie-Pierre Debray²⁵, Catherine Boileau¹², Raphaël Porcher²⁶, Bruno Crestani¹³, David A. Schwartz⁴ and Philippe Dieude²⁷, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²National Jewish Health, Denver, CO, ³Hôpital Cochin, Service de Rééducation, Paris, Paris, France, ⁴Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO, ⁵Service de Rhumatologie, CHU de Fort de France, Martinique, France, Fort de France, France, ⁶Interstitial Lung Disease & Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, México City, México, Mexico, Mexico, ⁷HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas. Mexico City, Mexico, Mexico, Mexico, ⁸2nd Pulmonary Medicine Department, University Hospital of Athens "Attikon", National and Kapodistrian University of Athens, Greece, Athens, Greece, ⁹Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, University Hospital of Athens "Attikon", National and Kapodistrian University of Athens, Greece, Athens, Greece, ¹⁰PS Department of Respiratory Medicine & Laboratory of Molecular & Cellular Pneumonology, Faculty of Medicine, University of Crete, Crete, Greece, Heraklion, Greece, ¹¹St Antonius ILD center of excellence, St Antonius ziekenhuis, Nieuwegein, The Netherlands, Nieuwegein, Netherlands, ¹²Université de Paris, Hôpital Bichat, Service de Génétique, AP-HP, Paris, Paris, France, ¹³Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ¹⁴CHRU de Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence des maladies pulmonaires rares, FHU IMMINENT, Lille, France, Lille, France, ¹⁵Lille University Hospital, Lille, France, ¹⁶Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, ¹⁷Hôpital Avicennes, Service de Pneumologie, AP-HP, Bobigny, Bobigny, France, ¹⁸Hôpital Avicenne, Service de pneumologie, AP-HP, Bobigny, Bobigny, France, ¹⁹Hôpital Avicennes, Service de Rhumatologie, AP-HP, Bobigny, Bobigny, France, ²⁰Hôpital Avicenne, Service de Rhumatologie, AP-HP, Bobigny, Bobigny, France, ²¹Rheumatology Hospital, Pelligrin Hospital, Bordeaux University Hospital, Bordeaux, France, ²²CHU de Bordeaux, Service de Rhumatologie, Bordeaux, France, ²³Brigham and Women's Hospital, West Roxbury, MA, ²⁴University of California, San Francisco, San Francisco, CA, ²⁵Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²⁶Centre d’Epidémiologie Clinique, AP-HP, Hôpital Hôtel-Dieu, F-75004 Paris, France, Paris, France, ²⁷Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) sharephenotypic and genotypic similarities. Recently, in a large international genetic association…
Abstract Number: 2039 • ACR Convergence 2020
Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma
Britany Adler¹, Ami Shah², Francesco Boin³, Paul Wolters³, Livia Casciola-Rosen⁴ and Antony Rosen¹, ¹Johns Hopkins University, baltimore, MD, ²Johns Hopkins University School of Medicine, Ellicott City, MD, ³University of California, San Francisco, San Francisco, CA, ⁴Johns Hopkins University, Johns Hopkins University, MD
Background/Purpose: Scleroderma is a systemic fibrosing disease of unknown etiology that often manifests with interstitial lung disease (ILD). Prior studies have found an association between…
Abstract Number: 0388 • ACR Convergence 2020
Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial
Masataka Kuwana¹, Shervin Assassi², Jérôme Avouac³, Rachel Hoyles⁴, Janet Pope⁵, Vanessa Smith⁶, Corinna Miede⁷, Emmanuelle Clerisme-Beaty⁸, Margarida Alves⁹ and Oliver Distler¹⁰, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ²University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ³Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris Descartes University, France, Paris, France, ⁴Department of Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, ⁷mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim, Germany, Ingelheim, Germany, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁰Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The progression of SSc-ILD is variable and unpredictable. However, observational studies have identified patient characteristics that may be prognostic of a greater rate of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].